ORTHOPEDIATRICS CORP 10-K

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES MARKET INFORMATION Our common stock has been listed on the Nasdaq Global Market under the symbol "KIDS" since October 12, 2017. Prior to that date, there was no established public trading market for our common stock. DIVIDEND POLICY We have not declared or paid any cash dividends on our common stock. We have no present intention to pay dividends in the foreseeable future, but rather intend to retain all of our consolidated earnings to finance future growth. Any future determination to pay dividends will be made at the discretion of our Board of Directors. See the “CAPITAL” section of “Management's Discussion & Analysis of Financial Condition and Results of Operations” included as Item 7 of this Annual Report on Form 10-K and Note 12 of the Notes to Consolidated Financial Statements included as Item 8 of this Annual Report on Form 10-K for a discussion regarding dividend restrictions. HOLDERS OF RECORD At the close of business on March 1, 2022, the number of shares outstanding was 19,745,348 . There were 175 stockholders of record on that date. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS There were no equity securities purchased by the issuer or any affiliated purchaser for the three months ended December 31, 2021. RECENT SALES OF UNREGISTERED SECURITIES On October 20, 2021, the Company issued 4,599 shares of its common stock, $0.00025 par value per share, in connection with the purchase of certain intellectual property assets and product inventory from Devise Ortho, Inc. The purchase price also included $0.650 million in cash. The shares were valued at $64.83 per share, representing the closing price per share on the date of issuance. The issuance of the common stock was made in reliance upon an exemption provided under Section 4(a)(2) of the Securities Act of 1933, as amended. EQUITY COMPENSATION PLAN INFORMATION The following table provides information about the Company’s common stock that may be issued under equity compensation plans as of December 31, 2021. Plan Category Number of securities to be issued upon exercise of outstanding options, warrants and rights Weighted-average exercised price of outstanding options, warrants and rights Number of securities remaining available for future issuance under equity compensations plans (excluding securities reflected in first column) Equity compensation plans approved by stockholders 375,084 $ 45.18 694,186 Total 375,084 $ 45.18 694,186 70 ITEM 6. [Reserved] Intentionally omitted.